Go to the list of all blogs
Anna G's Avatar
published in Blogs
Oct 15, 2023

Medical Distributors Surge: $CAH, $ZYXI, $PDCO, $COR, $MCK Gain +3.18%

Medical Distributors Surge: A Deeper Dive into Market Movements and Notable Tickers

πŸ“ˆ Medical Distributors experience a +3.18% gain in the past month. Current Buy/Sell Ratings suggest a Positive Outlook for stocks in the group.

Are you interested in the dynamic world of medical distributors and eager to optimize your trading strategies within this sector? Look no further! Our AI robots are tailored to meet your trading needs in the Group Medical Distributors arena.

πŸ€– "Swing Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" provides you with a reliable and data-driven approach to trading within this sector. Whether you're a seasoned trader or just starting, this AI tool can assist you in making informed decisions.

πŸ’Ό For those seeking to capitalize on upward market trends, "Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA)" offers a simplified yet effective strategy. It's designed to empower traders to navigate and thrive in markets on the rise.

With these AI robots by your side, you'll be well-equipped to explore trading opportunities and make data-backed decisions in the ever-evolving world of medical distributors. Elevate your trading game today!

Tickers in this Group:Β 
$EDAPΒ - $CAHΒ - $MCKΒ - $CORΒ -Β $HSICΒ -Β  $OMIΒ -Β $PDCOΒ - $ZYXI

The Landscape of Medical Distributors

Medical distributors play a pivotal role in the healthcare ecosystem, bridging the gap between manufacturers and providers. Their core services, ranging from product distribution to inventory management, contribute significantly to the US healthcare sector's value. As per a report by Deloitte, these services infuse a value of $33 billion-$53 billion annually. Major players in this sector include giants like McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc., and Patterson Companies, Inc.

Market Cap: The Financial Magnitude

The medical distributors' industry has a collective market cap averaging at 8.9B. The spectrum is vast - from $MCK at a towering 61.9B to a modest $SNYR at 494.4K.

High and Low Price Notable News: The Peaks and Valleys

  • Average weekly price growth: 2.39%
  • Average monthly price growth: 2.09%
  • Quarterly spike: 11.3%

Key Players:

  • $EXHID soars with the highest growth at 37.25%
  • $OMI takes a dip at -4.39%

Recent News Highlights:

  • 10/11/23: $CAH leaps with a +5.51% weekly increase.
  • 8/18/23: Both $OMI and $CAH saw declines, dropping by -14.46% and -6.44%, respectively.

Volume: The Trading Buzz

  • Weekly volume decline: -7.21%
  • Monthly volume decline: -56.61%
  • Quarterly volume increment: 0.2%

Fundamental Analysis Ratings: The Deep Dive

  • Valuation Rating: 66
  • P/E Growth Rating: 51
  • Price Growth Rating: 56
  • SMR Rating: 66
  • Profit Risk Rating: 73
  • Seasonality Score: 27 (Scale: -100 to +100)

Ticker Descriptions: Highlighting Key Players

πŸ” $CAH: Now trending upward after rising above its 50-day MA on October 04, 2023. Past trends suggest a 78% chance of continued uptrend.

πŸ” $ZYXI: Watch out! Entering the oversold zone as of October 13, 2023. Historically, it indicates potential for a price uptrend or consolidation soon.

πŸ” $PDCO: Positive vibes! MACD Histogram turned positive on September 21, 2023, with 82% chances of a continued rise.

πŸ” $COR: Bullish trend with the 10-day MA crossing over the 50-day MA on September 28, 2023. Past data indicates a 71% chance of continued upward movement.

πŸ” $MCK: Yet another MACD positive shift on September 12, 2023, with a strong 75% odds of maintaining the bullish trend.

πŸ” $EDAP: Positive MACD crossover on September 20, 2023, suggests an 84% probability of an upward trend in the coming month.

Β 

The Medical Distributors sector is currently buzzing with positive vibes, reflected in its impressive gains and overall positive outlook. Traders should closely monitor the described tickers and watch for further market shifts. As always, it's essential to make informed decisions and keep an eye on these notable market movers. Happy trading! πŸ“ŠπŸ“‰πŸ“ˆ

Related Ticker: FOCL, CAH, MCK, COR, HSIC, OMI, PDCO, ZYXI

FOCL in downward trend: price dove below 50-day moving average on August 12, 2026

FOCL moved below its 50-day moving average on August 12, 2026 date and that indicates a change from an upward trend to a downward trend. In of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for FOCL crossed bearishly below the 50-day moving average on August 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 192 cases where FOCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.212) is normal, around the industry mean (20.175). P/E Ratio (0.000) is within average values for comparable stocks, (43.238). FOCL's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.366). FOCL's Dividend Yield (0.000) is considerably lower than the industry average of (0.007). P/S Ratio (1.952) is also within normal values, averaging (6.528).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 18.78B. The market cap for tickers in the group ranges from 557.05K to 100.14B. MCK holds the highest valuation in this group at 100.14B. The lowest valued company is CNBI at 557.05K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -2%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -28%. ACH experienced the highest price growth at 26%, while AHG experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was -9% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 57
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 77
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
FOCL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of minimally invasive medical devices for urological diseases

Industry MedicalDistributors

Profile
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillipsΒ (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betasβ€”DEO (0.18), UL (0.24), and KDP (0.35)β€”highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.